Cite
HARVARD Citation
Fujiwara, K. et al. (n.d.). 263TiPATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer. Annals of oncology. p. . [Online].